论文部分内容阅读
目的:观察乳积方对女性乳腺癌术后患者生存状况及血清血管内皮生长因子(VEGF)水平的影响。方法:将76例乳腺癌改良根治术后患者随机分为2组各38例。对照组术后给予常规放、化疗和对症支持治疗。治疗组在对照组治疗方案的基础上加用乳积方治疗,放、化疗期间每天1剂,放、化疗结束后3个月期间,每天2剂,其后每周服用4剂,常规水煎分2次服用,共治疗1年。比较2组乳腺癌生活质量评分系统(FACT-B)、生活质量评分、总体健康质量,并检测2组血清中VEGF水平。结果:治疗1年,2组FACT-B中各指标评分明显升高,与治疗前比较,差异均有统计学意义(P<0.01);治疗后,治疗组FACT-B中各指标分别与对照组比较,差异均有统计学意义(P<0.01)。治疗1年,2组总体健康状况和总体生活质量评分明显升高,分别与治疗前比较,差异均有统计学意义(P<0.01);治疗1年,治疗组总体生活质量情况和总体健康状况评分分别与治疗前比较,差异均有统计学意义(P<0.01)。治疗1年,治疗组血清VEGF水平明显减少,且明显低于对照组,差异均有统计学意义(P<0.01)。治疗1年,对照组患者血清VEGF水平与治疗前比较,差异无统计学意义(P>0.05)。结论:乳积方辅助干预女性乳腺癌术后患者能改善生存状况,抑制其血清中VEGF水平。
Objective: To observe the effects of Rujifang on the survival of postoperative patients with breast cancer and the level of serum vascular endothelial growth factor (VEGF). Methods: 76 cases of modified radical mastectomy patients were randomly divided into two groups of 38 cases. The control group was given routine radiotherapy, chemotherapy and symptomatic supportive therapy. Treatment group in the control group based on the treatment program plus milk plot Fang treatment, radiotherapy and chemotherapy during the day 1, place, 3 months after the end of chemotherapy, 2 doses a day, then take 4 doses per week, conventional decoction Take 2 times, a total of 1 year treatment. The two groups of breast cancer quality of life score system (FACT-B), quality of life score, overall health quality were compared. The serum VEGF levels were also measured. Results: After 1 year of treatment, the score of each index of FACT-B in two groups was significantly higher than that before treatment (P <0.01). After treatment, the indexes of FACT-B in treatment group were respectively compared with those of control The differences between the two groups were statistically significant (P <0.01). After 1 year of treatment, the scores of overall health status and overall quality of life in two groups were significantly increased (P <0.01), respectively, compared with those before treatment (P <0.01). The overall quality of life and general health of the treatment group Scores were compared with before treatment, the difference was statistically significant (P <0.01). Treatment for 1 year, the treatment group serum VEGF levels were significantly lower, and significantly lower than the control group, the difference was statistically significant (P <0.01). After 1 year of treatment, serum VEGF level in the control group was not significantly different from that before treatment (P> 0.05). Conclusion: RuJifang assisted intervention in female patients with breast cancer can improve the survival status, inhibit the serum VEGF levels.